1,413 Shares in Laboratory Corp. of America Holdings (LH) Acquired by Commerzbank Aktiengesellschaft FI

Commerzbank Aktiengesellschaft FI acquired a new stake in shares of Laboratory Corp. of America Holdings (NYSE:LH) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 1,413 shares of the medical research company’s stock, valued at approximately $225,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Valeo Financial Advisors LLC bought a new position in Laboratory Corp. of America during the third quarter valued at approximately $444,000. Cubist Systematic Strategies LLC raised its position in Laboratory Corp. of America by 233.1% during the third quarter. Cubist Systematic Strategies LLC now owns 10,599 shares of the medical research company’s stock valued at $1,600,000 after acquiring an additional 7,417 shares in the last quarter. Tocqueville Asset Management L.P. raised its position in Laboratory Corp. of America by 1,906.0% during the third quarter. Tocqueville Asset Management L.P. now owns 32,677 shares of the medical research company’s stock valued at $4,933,000 after acquiring an additional 31,048 shares in the last quarter. Calamos Advisors LLC raised its position in Laboratory Corp. of America by 21.2% during the third quarter. Calamos Advisors LLC now owns 171,866 shares of the medical research company’s stock valued at $25,947,000 after acquiring an additional 30,017 shares in the last quarter. Finally, Veritas Investment Management UK Ltd raised its position in Laboratory Corp. of America by 46.1% during the third quarter. Veritas Investment Management UK Ltd now owns 67,533 shares of the medical research company’s stock valued at $10,195,000 after acquiring an additional 21,323 shares in the last quarter. 90.87% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages recently weighed in on LH. Zacks Investment Research raised shares of Laboratory Corp. of America from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. ValuEngine lowered shares of Laboratory Corp. of America from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. Craig Hallum reissued a “buy” rating and issued a $204.00 price target (up previously from $180.00) on shares of Laboratory Corp. of America in a research report on Wednesday. Mizuho set a $165.00 price target on shares of Laboratory Corp. of America and gave the company a “neutral” rating in a research report on Friday, December 1st. Finally, Barclays lifted their price target on shares of Laboratory Corp. of America from $183.00 to $190.00 and gave the company an “overweight” rating in a research report on Thursday, October 26th. Six equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $176.71.

Laboratory Corp. of America Holdings (NYSE LH) opened at $169.66 on Thursday. Laboratory Corp. of America Holdings has a 52-week low of $130.29 and a 52-week high of $181.71. The company has a market cap of $17,380.00, a P/E ratio of 13.88, a PEG ratio of 1.54 and a beta of 0.92. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.89 and a quick ratio of 1.75.

Laboratory Corp. of America (NYSE:LH) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $2.45 EPS for the quarter, beating the Zacks’ consensus estimate of $2.38 by $0.07. The company had revenue of $2.70 billion for the quarter, compared to analyst estimates of $2.70 billion. Laboratory Corp. of America had a net margin of 7.40% and a return on equity of 16.75%. The company’s quarterly revenue was up 13.2% compared to the same quarter last year. During the same quarter last year, the firm posted $2.15 earnings per share. sell-side analysts forecast that Laboratory Corp. of America Holdings will post 9.53 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “1,413 Shares in Laboratory Corp. of America Holdings (LH) Acquired by Commerzbank Aktiengesellschaft FI” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://sportsperspectives.com/2018/02/08/1413-shares-in-laboratory-corp-of-america-holdings-lh-acquired-by-commerzbank-aktiengesellschaft-fi.html.

Laboratory Corp. of America Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corp. of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply